<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Neuromuscular manifestations and WNV poliomyelitis:</italic> In the 1999 New York City outbreak, more than 50% of patients with confirmed WNV encephalitis had severe muscle weakness as a cardinal sign [
 <xref rid="B12-pathogens-08-00193" ref-type="bibr">12</xref>], and there were several case series that attributed neuromuscular complications, particularly acute flaccid paralysis, to peripheral nerve etiologies, namely Guillain–Barré syndrome (GBS), motor axonopathy, or severe axonal polyneuropathy [
 <xref rid="B12-pathogens-08-00193" ref-type="bibr">12</xref>,
 <xref rid="B20-pathogens-08-00193" ref-type="bibr">20</xref>,
 <xref rid="B21-pathogens-08-00193" ref-type="bibr">21</xref>]. In the 2002 and 2003 WNV epidemics, neuromuscular manifestations were a well-recognized feature associated with increased morbidity and mortality [
 <xref rid="B22-pathogens-08-00193" ref-type="bibr">22</xref>,
 <xref rid="B23-pathogens-08-00193" ref-type="bibr">23</xref>,
 <xref rid="B24-pathogens-08-00193" ref-type="bibr">24</xref>]. Neuromuscular manifestations are now recognized as a prominent feature in patients with WNV neuroinvasive disease [
 <xref rid="B25-pathogens-08-00193" ref-type="bibr">25</xref>].
</p>
